ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2024年11月26日

查看全文
  • Jacob K. Kresovich,
  • Catherine Guranich,
  • Serena Houghton,
  • Jing Qian,
  • Micheal E. Jones,
  • Maegan E. Boutot,
  • Mitch Dowsett,
  • A. Heather Eliassen,
  • Montserrat Garcia-Closas,
  • Peter Kraft,
  • Aaron Norman,
  • Michael Pollak,
  • Sabina Rinaldi,
  • Bernard Rosner,
  • Minouk J. Schoemaker,
  • Christopher Scott,
  • Anthony J. Swerdlow,
  • Roger L. Milne,
  • Shelley S. Tworoger,
  • Celine M. Vachon,
  • Susan E. Hankinson

摘要

Background

Prolactin, a hormone produced by the pituitary gland, regulates breast development and may contribute to breast cancer etiology. However, most epidemiologic studies of prolactin and breast cancer have been restricted to single, often small, study samples with limited exploration of effect modification.

Methods

The Biomarkers in Breast Cancer Risk Prediction consortium includes 8,279 postmenopausal women sampled from four prospective cohort studies, of whom 3,441 were diagnosed with invasive breast cancer after enrollment. Prolactin concentrations were measured for all study participants on plasma samples collected when all women were postmenopausal and before any breast cancer diagnosis using ELISA assays. Pooled, unconditional logistic regression models, adjusted for confounders, estimated odd ratios (OR) for associations of prolactin and postmenopausal breast cancer risk overall and stratified by breast cancer risk factors.

Results

Higher plasma prolactin concentrations were positively associated with postmenopausal breast cancer risk (> 13.2 ng/mL vs. < 7.9 ng/mL, OR: 1.20, 95% CI: 1.06, 1.36; P-trend < 0.001). Although associations did not appear to vary by time since blood draw or most breast cancer risk factors, associations were primarily observed in current users of postmenopausal hormones at blood draw (> 13.2 ng/mL vs. < 7.9 ng/mL, current users, OR: 1.58, 95% CI: 1.27, 1.96, P-trend < 0.001; non-current users, OR: 1.08, 95% CI: 0.93, 1.27, P-trend = 0.11; P-heterogeneity = 0.06).

Conclusion

Prolactin may be a risk factor for postmenopausal breast cancer, particularly in the context of postmenopausal hormone use. Investigations of prolactin interactions with other hormonal factors may further inform breast cancer etiology.